STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[SCHEDULE 13G] Alto Neuroscience, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Perceptive Advisors LLC, Perceptive Life Sciences Master Fund, Ltd. and Joseph Edelman disclosed a 7.3% beneficial ownership stake in Alto Neuroscience, Inc. (ticker ANRO), representing 1,989,393 shares of common stock. The filing states the ownership percentage is calculated from 27,076,629 outstanding shares as of August 8, 2025. The Master Fund directly holds the shares while Perceptive Advisors acts as investment manager and Mr. Edelman is the managing member, so each reporting person reports shared voting and dispositive power over the same block. The filing certifies the position is not held to change or influence control of the issuer.

Positive

  • Material disclosure: Reporting of a 7.3% stake ensures regulatory transparency for investors
  • Single-block ownership: All reporting persons disclose the same 1,989,393 shares, reducing ambiguity about overlapping claims

Negative

  • No sole voting or dispositive power reported, indicating limited unilateral influence over corporate decisions
  • 7.3% stake may still exert market influence without a control intent, creating potential activist interest or trading volatility

Insights

Perceptive reports a material >5% passive stake and shared control of 1.99M shares.

The reported 1,989,393 shares equal 7.3% of the outstanding common stock based on 27,076,629 shares as of August 8, 2025, which meets the disclosure threshold requiring a Schedule 13G.

This position is described as shared voting and dispositive power and certified as not acquired to change control, indicating a likely passive or investment-management holding. Investors should note the holding is large enough to be a visible institutional stake but the filers disclaim a control intent in the near term.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Perceptive Advisors LLC
Signature:/s/ Joseph Edelman
Name/Title:Joseph Edelman, Managing Member
Date:10/10/2025
Joseph Edelman
Signature:/s/ Joseph Edelman
Name/Title:Joseph Edelman
Date:10/10/2025
Perceptive Life Sciences Master Fund, Ltd.
Signature:/s/ Joseph Edelman
Name/Title:Joseph Edelman, Managing Member
Date:10/10/2025

FAQ

What stake did Perceptive report in Alto Neuroscience (ANRO)?

Perceptive Advisors, Perceptive Life Sciences Master Fund and Joseph Edelman each reported beneficial ownership of 1,989,393 shares, equal to 7.3% of outstanding common stock.

How was the 7.3% ownership percentage calculated?

The percentage is based on 27,076,629 outstanding shares of common stock as of August 8, 2025.

Does the filing indicate Perceptive seeks control of ANRO?

No. The certification states the securities were not acquired to change or influence control and no control intent is indicated.

Who holds voting and disposal power for the reported shares?

The Master Fund directly holds the shares; Perceptive Advisors and Joseph Edelman report shared voting and shared dispositive power over the same 1,989,393 shares.

When was the Schedule 13G signed?

The signatures are dated 10/10/2025.
Alto Neuroscienc

NYSE:ANRO

ANRO Rankings

ANRO Latest News

ANRO Latest SEC Filings

ANRO Stock Data

411.63M
26.80M
7.48%
64.06%
6.28%
Biotechnology
Pharmaceutical Preparations
Link
United States
MOUNTAIN VIEW